Boston Bio Systems Ltd Financials
Company Logo

Boston Bio Systems Ltd Financial Statement

Boston Bio Systems Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
RevenueTBA
Operating Expense0.01
Net Profit-0.01
Net Profit MarginTBA
Earning Per Share-0.01
EBIDTA-0.01
Effective Tax RateTBA
Invest in Boston Bio Systems Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions

Boston Bio Systems Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue AnnualTBA
Operating Expenses Annual0.14
Operating Profit Annual-0.14
Interest AnnualTBA
DepreciationTBA
Net Profit Annual-0.14
Tax AnnualTBA

Boston Bio Systems Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.05
Cash Flow from OperationsTBA
Cash Flow from InvestingTBA
Cash Flow from FinancingTBA
Cash Flow at the End0.05

Boston Bio Systems Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)TBA
PBIT Margin (%)TBA
PBT Margin (%)TBA
Net PROFIT Margin (%)TBA
Return On Networth / Equity (%)TBA
Return On Networth /Employed (%)TBA
Return On Assets (%)TBA
Total Debt / Equity (X)0.13
Asset Turnover Ratio (%)TBA

Boston Bio Systems Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets AnnualTBA
Total Current Assets Annual4.77
Non Current Assets Annual5.79
Total Shareholders Funds Annual6.45
Total Assets Annual10.57

Boston Bio Systems Ltd Earning Calls

No Data Availabe

Get Your FAQs Right

As of Nov 24, 2024, Boston Bio Systems Ltd has a market capitalization of - Cr. Value Research classifies it as a Micro-Cap company.
Yes, Boston Bio Systems Ltd is debt-free with a debt-to-equity ratio of 0.02.
In FY 2023 , Boston Bio Systems Ltd recorded a total revenue of approximately 0 Cr marking a significant milestone in the company's financial performance.
Boston Bio Systems Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately NaN% and -100.0% annually, respectively..
Boston Bio Systems Ltd's current PE ratio is undefined.
Boston Bio Systems Ltd's ROCE averaged -0.6% from the FY ending March 2018 to 2024, with a median of -0.0%. It peaked at 0.0% in March 2018, reflecting strong capital efficiency over the period..
Boston Bio Systems Ltd's latest EBIT is Rs. -0.14 Cr, surpassing the average EBIT of Rs. -0.05 Cr over the 5 years..